A register-based case-control study of prescription medication utilization in binge-eating disorder

Hunna J. Watson, A. Jangmo, M.A. Munn-Chernoff, L.M. Thornton, E. Welch, C. Wiklund, Y. von Hausswolff-Juhlin, C. Norring, B.K. Herman, H. Larsson, C.M. Bulik

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    © 2016 Physicians Postgraduate Press, Inc.Objective: Individuals with binge-eating disorder (BED) experience psychiatric and somatic comorbidities and obesity, but the nature and magnitude of prescription medication utilization is unclear. We investigated utilization using Swedish registry data and a case-control design. Methods: Cases were identified from Riksät and Stepwise longitudinal registers and were individuals diagnosed with BED per DSM-IV-TR criteria between July 1, 2006, and December 31, 2009, at eating disorder clinics (n = 238, 96% female, mean age = 22.8 years). For each case, 10 controls were matched on sex and year, month, and county of birth (n = 2,380). An index date was derived for each control, which was the date of diagnosis of BED in the corresponding case. The association between BED and prescription medication utilization was investigated before and within 12 months after diagnosis. Results: Before diagnosis, cases were significantly more likely than matched controls to have been prescribed nervous system (odds ratio = 6.4; 95% confidence limit = 4.7, 8.6), tumors and immune disorders (3.5; 1.3, 9.3), cardiovascular (2.2; 1.4, 3.5), digestion and metabolism (2.1; 1.5, 2.9), infectious diseases (1.9; 1.4, 2.6), skin (1.8; 1.3, 2.5), and respiratory system (1.3; 1.0, 1.8) medications. Cases also had higher odds of prescription use than controls across most categories within 12 months after diagnosis. Several associations were significant after accounting for lifetime psychiatric comorbidity and obesity. Conclusions: Individuals with BED had increased utilization of psychiatric and nonpsychiatric medications compared with matched controls. Findings confirm that the illness burden of BED extends to high medication utilization and underscore the importance of thorough medication reviews when treating individuals with BED.
    Original languageEnglish
    JournalPrimary Care Companion to the Journal of Clinical Psychiatry
    Volume18
    Issue number4
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Binge-Eating Disorder
    Prescriptions
    Case-Control Studies
    Psychiatry
    Comorbidity
    Obesity
    Cost of Illness
    Immune System Diseases
    Diagnostic and Statistical Manual of Mental Disorders
    Respiratory System
    Nervous System
    Communicable Diseases
    Registries
    Digestion
    Odds Ratio
    Parturition
    Physicians
    Skin

    Cite this

    Watson, Hunna J. ; Jangmo, A. ; Munn-Chernoff, M.A. ; Thornton, L.M. ; Welch, E. ; Wiklund, C. ; von Hausswolff-Juhlin, Y. ; Norring, C. ; Herman, B.K. ; Larsson, H. ; Bulik, C.M. / A register-based case-control study of prescription medication utilization in binge-eating disorder. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2016 ; Vol. 18, No. 4.
    @article{16cc06ad6e834ec4a3f6f4070af45200,
    title = "A register-based case-control study of prescription medication utilization in binge-eating disorder",
    abstract = "{\circledC} 2016 Physicians Postgraduate Press, Inc.Objective: Individuals with binge-eating disorder (BED) experience psychiatric and somatic comorbidities and obesity, but the nature and magnitude of prescription medication utilization is unclear. We investigated utilization using Swedish registry data and a case-control design. Methods: Cases were identified from Riks{\"a}t and Stepwise longitudinal registers and were individuals diagnosed with BED per DSM-IV-TR criteria between July 1, 2006, and December 31, 2009, at eating disorder clinics (n = 238, 96{\%} female, mean age = 22.8 years). For each case, 10 controls were matched on sex and year, month, and county of birth (n = 2,380). An index date was derived for each control, which was the date of diagnosis of BED in the corresponding case. The association between BED and prescription medication utilization was investigated before and within 12 months after diagnosis. Results: Before diagnosis, cases were significantly more likely than matched controls to have been prescribed nervous system (odds ratio = 6.4; 95{\%} confidence limit = 4.7, 8.6), tumors and immune disorders (3.5; 1.3, 9.3), cardiovascular (2.2; 1.4, 3.5), digestion and metabolism (2.1; 1.5, 2.9), infectious diseases (1.9; 1.4, 2.6), skin (1.8; 1.3, 2.5), and respiratory system (1.3; 1.0, 1.8) medications. Cases also had higher odds of prescription use than controls across most categories within 12 months after diagnosis. Several associations were significant after accounting for lifetime psychiatric comorbidity and obesity. Conclusions: Individuals with BED had increased utilization of psychiatric and nonpsychiatric medications compared with matched controls. Findings confirm that the illness burden of BED extends to high medication utilization and underscore the importance of thorough medication reviews when treating individuals with BED.",
    author = "Watson, {Hunna J.} and A. Jangmo and M.A. Munn-Chernoff and L.M. Thornton and E. Welch and C. Wiklund and {von Hausswolff-Juhlin}, Y. and C. Norring and B.K. Herman and H. Larsson and C.M. Bulik",
    year = "2016",
    doi = "10.4088/PCC.16m01939",
    language = "English",
    volume = "18",
    journal = "Primary Care Companion to the Journal of Clinical Psychiatry",
    issn = "1523-5998",
    publisher = "Physicians Postgraduate Press, Inc",
    number = "4",

    }

    Watson, HJ, Jangmo, A, Munn-Chernoff, MA, Thornton, LM, Welch, E, Wiklund, C, von Hausswolff-Juhlin, Y, Norring, C, Herman, BK, Larsson, H & Bulik, CM 2016, 'A register-based case-control study of prescription medication utilization in binge-eating disorder' Primary Care Companion to the Journal of Clinical Psychiatry, vol. 18, no. 4. https://doi.org/10.4088/PCC.16m01939

    A register-based case-control study of prescription medication utilization in binge-eating disorder. / Watson, Hunna J.; Jangmo, A.; Munn-Chernoff, M.A.; Thornton, L.M.; Welch, E.; Wiklund, C.; von Hausswolff-Juhlin, Y.; Norring, C.; Herman, B.K.; Larsson, H.; Bulik, C.M.

    In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 18, No. 4, 2016.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A register-based case-control study of prescription medication utilization in binge-eating disorder

    AU - Watson, Hunna J.

    AU - Jangmo, A.

    AU - Munn-Chernoff, M.A.

    AU - Thornton, L.M.

    AU - Welch, E.

    AU - Wiklund, C.

    AU - von Hausswolff-Juhlin, Y.

    AU - Norring, C.

    AU - Herman, B.K.

    AU - Larsson, H.

    AU - Bulik, C.M.

    PY - 2016

    Y1 - 2016

    N2 - © 2016 Physicians Postgraduate Press, Inc.Objective: Individuals with binge-eating disorder (BED) experience psychiatric and somatic comorbidities and obesity, but the nature and magnitude of prescription medication utilization is unclear. We investigated utilization using Swedish registry data and a case-control design. Methods: Cases were identified from Riksät and Stepwise longitudinal registers and were individuals diagnosed with BED per DSM-IV-TR criteria between July 1, 2006, and December 31, 2009, at eating disorder clinics (n = 238, 96% female, mean age = 22.8 years). For each case, 10 controls were matched on sex and year, month, and county of birth (n = 2,380). An index date was derived for each control, which was the date of diagnosis of BED in the corresponding case. The association between BED and prescription medication utilization was investigated before and within 12 months after diagnosis. Results: Before diagnosis, cases were significantly more likely than matched controls to have been prescribed nervous system (odds ratio = 6.4; 95% confidence limit = 4.7, 8.6), tumors and immune disorders (3.5; 1.3, 9.3), cardiovascular (2.2; 1.4, 3.5), digestion and metabolism (2.1; 1.5, 2.9), infectious diseases (1.9; 1.4, 2.6), skin (1.8; 1.3, 2.5), and respiratory system (1.3; 1.0, 1.8) medications. Cases also had higher odds of prescription use than controls across most categories within 12 months after diagnosis. Several associations were significant after accounting for lifetime psychiatric comorbidity and obesity. Conclusions: Individuals with BED had increased utilization of psychiatric and nonpsychiatric medications compared with matched controls. Findings confirm that the illness burden of BED extends to high medication utilization and underscore the importance of thorough medication reviews when treating individuals with BED.

    AB - © 2016 Physicians Postgraduate Press, Inc.Objective: Individuals with binge-eating disorder (BED) experience psychiatric and somatic comorbidities and obesity, but the nature and magnitude of prescription medication utilization is unclear. We investigated utilization using Swedish registry data and a case-control design. Methods: Cases were identified from Riksät and Stepwise longitudinal registers and were individuals diagnosed with BED per DSM-IV-TR criteria between July 1, 2006, and December 31, 2009, at eating disorder clinics (n = 238, 96% female, mean age = 22.8 years). For each case, 10 controls were matched on sex and year, month, and county of birth (n = 2,380). An index date was derived for each control, which was the date of diagnosis of BED in the corresponding case. The association between BED and prescription medication utilization was investigated before and within 12 months after diagnosis. Results: Before diagnosis, cases were significantly more likely than matched controls to have been prescribed nervous system (odds ratio = 6.4; 95% confidence limit = 4.7, 8.6), tumors and immune disorders (3.5; 1.3, 9.3), cardiovascular (2.2; 1.4, 3.5), digestion and metabolism (2.1; 1.5, 2.9), infectious diseases (1.9; 1.4, 2.6), skin (1.8; 1.3, 2.5), and respiratory system (1.3; 1.0, 1.8) medications. Cases also had higher odds of prescription use than controls across most categories within 12 months after diagnosis. Several associations were significant after accounting for lifetime psychiatric comorbidity and obesity. Conclusions: Individuals with BED had increased utilization of psychiatric and nonpsychiatric medications compared with matched controls. Findings confirm that the illness burden of BED extends to high medication utilization and underscore the importance of thorough medication reviews when treating individuals with BED.

    U2 - 10.4088/PCC.16m01939

    DO - 10.4088/PCC.16m01939

    M3 - Article

    VL - 18

    JO - Primary Care Companion to the Journal of Clinical Psychiatry

    JF - Primary Care Companion to the Journal of Clinical Psychiatry

    SN - 1523-5998

    IS - 4

    ER -